Article Text

From adolescent PCOS to adult MAFLD: opposing effects of randomised interventions
  1. Francis de Zegher1,
  2. Marta Diaz2,
  3. Lourdes Ibañez2
  1. 1Department of Development and Regeneration, KU Leuven University Hospitals Leuven, Leuven, Belgium
  2. 2Department of Endocrinology, Hospital Sant Joan de Déu, Barcelona, Spain
  1. Correspondence to Professor Lourdes Ibañez, Hospital Sant Joan de Déu, Barcelona 08950, Spain; libanez{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Asfari et al reported that non-alcoholic fatty liver disease (NAFLD) is fourfold more prevalent in women with than without PCOS, and concluded that ‘further studies are needed to assess if specific PCOS treatments can affect NAFLD progression’.1

In the meantime, an international consensus has replaced NAFLD by metabolic dysfunction-associated fatty liver disease (MAFLD).2 In the absence of overweight and obesity, the definition of MAFLD requires not only that steatosis be present, but also that at least two markers point to metabolic dysfunction, for example, a circulating concentration of C reactive protein (CRP) >2.0 mg/L, and an Homeostasis Model Assessment-Insulin Resistance (HOMA-IR) value ≥2.5.

Adolescent polycystic ovary syndrome (PCOS) is a prevalent condition (≈10% of girls and women between 2 and 8 years postmenarche) that is characterised by androgen excess and menstrual irregularity (as a proxy of oligoanovulation)3 but seems to be driven by ectopic lipid accumulation in the liver, essentially resulting from a mismatch between (reduced) prenatal weight gain and (augmented) postnatal weight gain.4 5 Adolescent PCOS is increasingly viewed as a state of metabolic dysfunction, often with low-grade inflammation (by CRP) and/or insulin resistance (by HOMA-IR); a polycystic appearance of the ovaries is no longer a diagnostic criterion of PCOS in adolescence.3 4 6

The new definitions of MAFLD and adolescent PCOS have led to the insight that there may be an overlap between both entities, and that interventions for PCOS in late adolescence could indeed influence the prevalence of MAFLD in early adulthood. We investigated the latter possibility by taking advantage of recent data from randomised pilot studies in non-obese adolescents with PCOS.6 These studies compared the effects of a widely recommended treatment (targeting the ovaries) to those of a new treatment (targeting ectopic fat), each on top of lifestyle measures.6 The recommended treatment was an oestroprogestagen contraceptive (OC; 20 µg ethinylestradiol plus 100 mg levonorgestrel for 21/28 days, and placebo for 7/28 days) that silences the gonadotropic axis, thereby reducing the androgen excess and ensuring anovulation.7 8 The new treatment was a low-dose combination of three generics (SPIOMET),6 namely spironolactone 50 mg/day (to activate brown adipose tissue),9 pioglitazone 7.5 mg/day (to double high-molecular-weight adiponectinaemia,10 and to prioritise subcutaneous adipogenesis)11 and metformin 850 mg/day (to triple the circulating concentrations of appetite-attenuating GDF15).12 SPIOMET does not elicit a loss of body weight, but redistributes body fat from ectopic to subcutaneous depots, thereby conferring more broadly normalising benefits than OC, in particular on liver fat (by MRI) and on post-treatment androgen excess and ovulation rate6 13 (online supplemental table 1).

Here, we highlight the effects of OC versus SPIOMET intervention on a key MAFLD ensemble in non-obese young women with PCOS, namely the triad of hepatic fat, HOMA-IR and circulating CRP.6 Figure 1 shows that the randomised interventions were accompanied by opposing influences on these MAFLD components, so that the prevalence of the MAFLD triad increased from 13% to 35% during OC treatment, and decreased from 13% to 0% during SPIOMET treatment (p<0.001 for between-group difference at 6 and 12 months, by χ2 test). Mean body mass index increased over 12 months on OC (from 24.2 to 24.9 kg/m2; p≤0.01) but did not change detectably on SPIOMET (from 24.2 to 23.9 kg/m2).6

Figure 1

Opposing effects of randomised interventions on the MAFLD triad of hepatic fat, HOMA-IR and circulating CRP in adolescent girls with polycystic ovary syndrome (PCOS). Adolescents with PCOS (mean age 16 years) were randomised to receive an oestro-progestagen contraceptive (OC; red) or a low-dose combination of spironolactone-pioglitazone-metformin (SPIOMET; blue). On-treatment (0–12 months) results are shown as mean and SEM; n=31 in each treatment group. The dotted line in the hepatic-fat panel refers to the average fraction in healthy controls.6 The dotted lines in the HOMA-IR and CRP panels refer to the cut-off levels for these MAFLD criteria.2 Original data are from reference 6. CRP, C reactive protein; MAFLD, metabolic dysfunction-associated fatty liver disease.

In conclusion, the new MAFLD concept unmasks that the widely recommended OC therapy for PCOS does not attenuate the underpinning problem of metabolic dysfunction, and that approximately one-third of OC-treated non-obese adolescents with PCOS become young women with MAFLD. SPIOMET treatment represents a more pathophysiological approach: it is a weight-loss-mimicking intervention that normalises liver fat, HOMA-IR and circulating CRP, and that may be particularly preferable in adolescent settings of sexual abstinence, where contraception is not at stake. PCOS in adolescent girls and young women is, in essence, a postmenarcheal or pregestational central obesity syndrome (PCOS) that should not only be treated from a gynaecological but also from a hepatological perspective. OCs should be prescribed with more caution, and metabolic corrections should receive more attention. It is a shared responsibility to prevent that millions of non-obese adolescents with PCOS continue to become young women with both PCOS and MAFLD.

Ethics statements

Patient consent for publication


Supplementary materials

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.


  • Contributors FdZ wrote the Communication; MD researched data and reviewed/edited the text; LI contributed to data interpretation and reviewed/edited the text.

  • Funding This study was supported by the Ministerio de Ciencia e Innovación, Instituto de Salud Carlos III, and by the Fondo Europeo de Desarrollo Regional (FEDER) (PI15/01078). This work is also supported by a grant PERIS-SLT006/17/00140 from the AQU, Generalitat de Catalunya, Spain.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.